CODX Co-Diagnostics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CODX

Price (delayed)

$1.295

Market cap

$39.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$32.41M

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using ...

Highlights
The company's debt fell by 6% QoQ
The company's gross profit has shrunk by 94% YoY and by 42% QoQ
The revenue has plunged by 91% YoY and by 36% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://codiagnostics.com
Peers: OM OBIO

Key stats

What are the main financial stats of CODX
Market
Shares outstanding
30.58M
Market cap
$39.6M
Enterprise value
$32.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
8.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.96
Earnings
Revenue
$4.66M
EBIT
-$52.31M
EBITDA
-$51.05M
Free cash flow
-$22.51M
Per share
EPS
-$1.4
Free cash flow per share
-$0.77
Book value per share
$3.23
Revenue per share
$0.16
TBVPS
$2.8
Balance sheet
Total assets
$108.68M
Total liabilities
$9.19M
Debt
$3.04M
Equity
$99.49M
Working capital
$66.21M
Liquidity
Debt to equity
0.03
Current ratio
13.99
Quick ratio
12.6
Net debt/EBITDA
0.14
Margins
EBITDA margin
-1,095.8%
Gross margin
62.8%
Net margin
-913.7%
Operating margin
-1,223.7%
Efficiency
Return on assets
-36.9%
Return on equity
-39.8%
Return on invested capital
-71.8%
Return on capital employed
-50.5%
Return on sales
-1,123%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CODX stock price

How has the Co-Diagnostics stock price performed over time
Intraday
-1.89%
1 week
9.75%
1 month
6.15%
1 year
-55.34%
YTD
-48.61%
QTD
22.17%

Financial performance

How have Co-Diagnostics's revenue and profit performed over time
Revenue
$4.66M
Gross profit
$2.93M
Operating income
-$57M
Net income
-$42.56M
Gross margin
62.8%
Net margin
-913.7%
The company's gross profit has shrunk by 94% YoY and by 42% QoQ
The revenue has plunged by 91% YoY and by 36% from the previous quarter
The company's net margin has shrunk by 76% QoQ
Co-Diagnostics's operating margin has plunged by 64% from the previous quarter

Growth

What is Co-Diagnostics's growth rate over time

Valuation

What is Co-Diagnostics stock price valuation
P/E
N/A
P/B
0.4
P/S
8.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.96
CODX's EPS is down by 13% since the previous quarter
The P/B is 89% below the 5-year quarterly average of 3.8 but 2.5% above the last 4 quarters average of 0.4
The equity has declined by 26% year-on-year and by 3.8% since the previous quarter
The P/S is 93% above the last 4 quarters average of 4.3 but 89% below the 5-year quarterly average of 76.0
The revenue has plunged by 91% YoY and by 36% from the previous quarter

Efficiency

How efficient is Co-Diagnostics business performance
CODX's return on invested capital has dropped by 188% year-on-year but it is up by 10% since the previous quarter
CODX's return on sales has dropped by 72% since the previous quarter
CODX's return on equity is down by 22% since the previous quarter
The ROA has contracted by 22% from the previous quarter

Dividends

What is CODX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CODX.

Financial health

How did Co-Diagnostics financials performed over time
Co-Diagnostics's total liabilities has decreased by 29% YoY
The company's total assets fell by 26% YoY and by 3.7% QoQ
The company's debt is 97% lower than its equity
The equity has declined by 26% year-on-year and by 3.8% since the previous quarter
The company's debt fell by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.